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In recent years, the phrase ‘genomic medicine’ has increasingly been used to describe a new 
development in medicine that holds great promise for human health. This new approach to health 
care uses the knowledge of an individual’s genetic make-up to identify those that are at a higher 
risk of developing certain diseases and to intervene at an earlier stage to prevent these diseases. 
Identifying genes that are involved in disease aetiology will provide researchers with tools to 
develop better treatments and cures. A major role within this field is attributed to ‘predictive 
genomic medicine’, which proposes screening healthy individuals to identify those who carry 
alleles that increase their susceptibility to common diseases, such as cancers and heart disease. 
Physicians could then intervene even before the disease manifests and advise individuals with a 
higher genetic risk to change their behaviour—for instance, to exercise or to eat a healthier diet—
or offer drugs or other medical treatment to reduce their chances of developing these diseases. 
These promises have fallen on fertile ground among politicians, health-care providers and the 
general public, particularly in light of the increasing costs of health care in developed societies. 
Various countries have established databases on the DNA and health information of whole 
populations as a first step towards genomic medicine. Biomedical research has also identified a 
large number of genes that could be used to predict someone’s risk of developing a certain 
disorder. But it would be premature to assume that genomic medicine will soon become reality, as 
many problems remain to be solved. Our knowledge about most disease genes and their roles is 
far from sufficient to make reliable predictions about a patient’s risk of actually developing a 
disease. In addition, genomic medicine will create new political, social, ethical and economic 
challenges that will have to be addressed in the near future. 
 During the past several decades, biomedical research has identified almost 1,500 so-
called mendelian disorders, in which a mutation in a single gene predicts a high risk of developing 
a disease (Yoon et al, 2000). But genetic testing for these disorders—of which Huntington’s 
disease is the most prominent example—has had only a limited impact on health care for two 
reasons. First, few effective interventions are available to treat or prevent many of these 
conditions, other than contraception or abortion of an affected fetus, and second, these conditions 
collectively account for only 5%of the total disease burden in developed countries (Khoury et al, 
2004). The vast majority of illnesses are common multifactorial disorders, namely heart disease, 
cancers, major depression, arthritis, asthma and diabetes (Murray & Lopez, 1997). Nevertheless, 
family and twin studies indicate that, in addition to environmental risk factors, there is indeed a 
substantial genetic contribution to the aetiology of many of these disorders. Heritability estimates 
for these conditions and some of their biological risk factors range from 39% to 80% (Evans et al, 
2003), which suggests that it may be possible to identify those genes and use them for predictive 
tests. Although research has identified a few single dominant genes that are strongly associated 
with disease risk, such as BRCA1 and BRCA2 in breast cancer and FAP in colorectal cancer, these 
represent a minority of disease cases, and finding new alleles that predict susceptibility to most 
common diseases remains a major challenge (Schork, 1997). The main strategy used so far has 
been to look for associations between a disorder and either genetic markers or specific candidate 
alleles. Both types of study typically involve a case–control design to compare the prevalence of 
specific alleles, genotypes or genetic markers (for example, single-nucleotide polymorphisms, 
SNPs) in individuals who have the disease with matched controls (Hirschhorn et al, 2002; 
Zondervan & Cardon, 2004). The results have been disappointing. Meta-analyses of association 
studies to identify susceptibility alleles for heart disease, cancers, depression, asthma and diabetes 
have shown that many initially positive findings have not been replicated in later studies 
(Hirschhorn et al, 2002). Furthermore, the associations that have been replicated are rather 
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modest: typically, people with these susceptibility alleles are 1.2–1.5 times more likely to develop 
these disorders (Ioannidis, 2003). The failure to successfully identify susceptibility genes has been 
attributed to several factors: using study samples that are too small to detect modest associations; 
poor sampling and study design; using genetic markers that are only modestly correlated with 
‘disease genes’; and bias on the part of journals that favour the publication of early positive asso-
ciations over failed replications (Hirschhorn et al, 2002; Colhoun et al, 2003; Zondervan & Cardon, 
2004). 
 All these factors do have a role, but a more troubling possibility is that the failure to 
replicate many association studies may instead reflect the complexity of the genetics of common 
diseases. Although some authors take an optimistic stance and suggest that these diseases may be 
influenced by only a small number of rare alleles (Risch, 2001), the more popular view now is that 
these disorders are polygenic (Balmain et al, 2003; Pharoah et al, 2002). Thus, modest associations 
between susceptibility alleles and disease would be the ‘norm’, and genes such as FAP, BRCA1 
and BRCA2 would be the exception. Plausible estimates of the number of susceptibility alleles for 
major cancers range between tens and hundreds (Peto, 2001, 2002), all of which increasedisease 
risk only modestly because their effects depend on interactions with other genes and with the 
environment. Consequently, the success of genetic map-ping efforts to improve the prediction of 
dis ease risk will depend on various factors: the number of genes influencing each condition; the 
frequency of susceptibility alleles in the population; the penetrance of these alleles (how strongly 
they predict disease risk); how these alleles interact with each other, and under different genetic 
backgrounds; and interactions between these alleles and other risk factors. 
Optimists point to the ‘common disease, common variant’ (CDCV) hypothesis, which states that 
susceptibility alleles for common diseases reflect mutations that occurred in the human population 
100,000 years ago (Balmain et al 2003), which can therefore be identified in large association 
studies with 1000 to 5000 cases and controls (Zondervan & Cardon 2004). But if the CDCV 
hypothesis turns out to be false, the prospects for predictive genomics are rather bleak. If there are 
large numbers of novel mutations for each common disease and if these mutations occur with low 
frequency and vary between populations, it will be very difficult to identify susceptibility alleles for 
these diseases, even in extremely large case control studies using full genome scans (Wright & 
Hastie 2001; Balmain et al 2003). Further research will show which side is correct. But even if the 
optimists prevail, other major challenges for genomic medicine remain, mainly in developing tests 
and effective treatments, and in public health policy and ethics. 
First there is simply not yet enough knowledge about susceptibility genes and their role in the 
development of most diseases, which limits our ability to design efficient tests to predict disease 
risk with some reliability. Of the genetic tests available, fewer than 5% test for susceptibility to 
common diseases (Yoon et al, 2000) and most of these use rare alleles with a high predictive 
power. Sceptics therefore maintain that predictive genetic screening for polygenic disorders will 
not prove feasible. They argue that single alleles will be poor indicators of disease risk unless the 
lifetime risk of the disease is 5% or more and the genotype is either rare or increases disease risk 
20 times or more (Holtzman & Marteau, 2000; Khoury et al, 2004; Wald et al, 1999). Others 
contend that it will simply be economically unviable for a country’s healthcare system to screen the 
whole population for susceptibility alleles to prevent only a small number of these disorders (Vineis 
et al, 2001). 
Advocates of predictive genomics counter that testing of multiple genetic variants, which are 
individually only weak factors, might nevertheless give a better prediction of future disease risk 
(Khoury, 2003). Indeed, simulations of plausible scenarios indicate that such tests could 
substantially improve if multiple susceptibility alleles were tested and the results combined 
statistically to produce a risk score (Khoury et al, 2004; Pharoah et al, 2002). The efficiency of 
genomic screening could be further enhanced if the decision to test for multiple susceptibility 
alleles was based on a person’s family history of the disease (Khoury, 2003; Khoury et al, 2003). 
Indeed, such knowledge is a good risk factor for all major common diseases and it could be used to 
stratify the population into three broad risk groups. The average-risk group would have no affected 
first-degree relatives; the moderate-risk group would have a family history of late-onset disorders; 
and the high-risk group would have two or more affected first-degree relatives or a first-degree 
relative with an early onset of the disorder (Khoury, 2003). Scheuner et al (1997) estimated that 
30%–50% of the population would fall into the moderate-risk group, 10% into the high-risk group 
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and 40%–60% in the average-risk group. Triaging genetic screening on the basis of family history 
could approximately halve the number of people to be tested and improve the performance of 
genetic tests in people whose environment and behaviour place them at increased risk of 
developing the disorder. Epidemiological modelling of breast cancer genetics suggests that addi-
tional genetic information based solely on family history indeed improves predictions (Pharoah et 
al, 2002), but more direct evaluations are needed. 
 Although the scientific problems mentioned above may be solved through biomedical research in 
the near future, the possibility of predicting someone’s risk of developing a common polygenic 
disorder also raises ethical, social and policy challenges that science alone cannot address. 
Screening whole or subpopulations for a large number of susceptibility alleles is only socially 
and economically justifiable if physicians can follow up on a diagnosis of increased risk with an 
effective intervention to prevent this disorder (Evans et al, 2001; Rose, 1992; Khoury et al, 
2003). For some common cancers, such as colorectal and breast cancer, regular monitoring and 
early treatment have been shown to reduce fatality. Preventive medications to treat hyper-
cholesterolaemia and high blood pressure also exist, but are prescribed on the basis of traditional 
diagnoses of symptoms. It will take some time and large controlled trials to indicate whether 
intervening with healthy individuals who are at increased genetic risk of developing a given 
disease reduces premature mortality. 
Although some medications and other treatments exist, most interventions aimed at reducing 
disease risk still depend on the patient changing his or her behaviour. Much needs to be learned 
about how to present and explain information about genetic risks for common disorders to 
achieve this goal (Bottorff et al, 1998; Edwards et al, 2003). Whether simply giving individuals 
this information motivates them to change their lifestyle, such as quitting smoking (Khoury, 
2003), remains to be seen. Some researchers have already become concerned that inappropriate 
communication of risks may instead result in demoralization and reduce a person’s self-
confidence in their ability to change their health behaviour (Wright et al, 2003). A recent review 
(Braithwaite et al, 2004) indicated that genetic counselling does not lead to adverse outcomes, 
but further research on this topic is needed. 
Probability and relative risk data are difficult for most people to understand, and we need to 
consider using natural frequencies, a common denominator, framing both positive and negative 
perspectives and using visual aids (Gigerenzer, 2002; Gigerenzer & Edwards, 2003; Paling, 
2003; Robins & Metcalfe, 2004). Research on risk communication also highlights the 
importance of social and linguistic contexts in explaining to patients their personal risk score for 
common diseases (Alaszewski & Horlick-Jones, 2003; Moxey & Sanford, 2000). 
A related concern is that screening will unnecessarily raise anxiety about disease risk in 
individuals who are found to have susceptibility alleles, but who are at low risk of developing the 
disorder (Marteau & Croyle, 1998). Furthermore, there is no evidence that genetically based risk 
information gives a stronger motivation to change health behaviour than classic family history 
information (Hicken & Tucker, 2002). Clearly, the success of genomic medicine will depend 
largely on finding effective ways of communicating genetic risk to induce desirable changes in 
behaviour. 
In addition, there are concerns that genomic medicine and widespread screening will affect 
classic public health policies that address and reduce overall health risks in the population. 
These strategies aim, for instance, to reduce the prevalence of cigarette smoking or per capita 
alcohol consumption or to advise people to eat healthily and exercise regularly to reduce high 
blood pressure, diabetes, and heart and lung diseases (Rose, 1992). By contrast, the ‘high-risk’ 
strategy (Rose, 1992) of predictive genomic medicine shifts the focus to targeting individuals 
who have been identified as having a high genetic risk of developing a disease (Khoury et al, 
2004). Thus, important policy questions for genomic medicine will be ‘When should public 
health officials use population-based strategies?’ and ‘When should they identify and intervene 
with those at highest genetic risk?’ 
There are clearly some cases in which population strategies are more efficient. It is a more 
sensible policy to reduce cigarette smoking by high taxation on tobacco products and restrictions 
on cigarette advertising than by spending resources on identifying those at increased genetic risk 
of becoming nicotine dependent or developing tobacco-related diseases if they smoke (Hall et 
al, 2002; Khoury et al, 2004). Similar arguments have recently been made in favour of 
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prescribing a ‘polypill’ to all adults over 50 years of age as an efficient way of reducing 
cardiovascular disease mortality by 80% in developed societies (Wald & Law, 2003). But genomic 
medicine may shift the focus, and funds, away from public health policies. A major challenge for 
policy makers will therefore be to reap the health benefits of genomic medicine without 
undermining effective public health policies (Khoury et al, 2004). 
The concerns about the ethical and policy implications of genetic testing have been much 
influenced by the mendelian disorders, such as Huntington’s disease. Because the mutations that 
cause this serious disorder are strongly predictive, genetic testing creates serious ethical and 
other dilemmas for affected individuals and their families (Marteau & Richards, 1996). It also 
raises real concerns that health and life insurers and employers might make discriminatory use 
of this information (Billings et al, 1992; Taylor, 1998). But, as pointed out above, the mendelian 
disorders represent only a small number of cases compared with the overall incidence of 
common polygenic diseases. And the discussion of the ethical implications of predictive 
genomics has not even begun to consider efficient strategies for its use in preventing these 
diseases. If the pessimists are right, these ethical and policy issues will not arise at all, because 
we will not be able to identify any useful predictive alleles for common diseases. 
Even in the most optimistic scenario, predictive genomics will not test whole populations for 
mendelian mutations. Instead, predictive genetic testing may be offered to 20%–50% of the 
population on the basis of a family history of disease. A minority of those tested would have rare 
quasimendelian forms of some common diseases, such as FAP for colorectal cancer, or BRCA1 or 
BRCA2 for breast cancer. In these cases, the ethical issues identified with mendelian disorders—
namely, discrimination and concerns about third-party use of genetic information—would have 
to be addressed. The majority of individuals with a family history, however, would just have an 
elevated risk score as defined by a number of common susceptibility alleles. 
Fear of discrimination may nonetheless deter people from taking genetic tests that could 
benefit them. Similar fears may also discourage individuals from participating in research on 
common diseases, thereby impairing the acquisition of knowledge for efficient prevention and 
treatment of serious diseases, which would benefit the community in the long term. It remains to 
be seen how concerns about third-party use of genetic information, possible discrimination and 
stigmatization will impede the success of predictive genomics. Governments and industry will 
have to address these issues in ways that are understood and accepted by the public. 
Another major challenge for implementing predictive genomic medicine in health care will be 
to educate the public about its benefits and shortcomings. Current understanding of genetics 
among the general public (Morris et al, 2003; Richards & Ponder, 1996) and health providers 
(Robins & Metcalfe, 2004) is not high, but it would be wrong to assume that the public will be 
only passive consumers of information about genetics (Dietrich & Schibeci, 2003). Popular 
understanding of genetics is often deterministic, with many people believing that if you have ‘the 
gene for X’ you are very likely to develop that disorder and, conversely, that you will be at low 
risk of doing so if you do not have this gene (Khoury et al, 2000). These views reflect the 
media’s focus on mendelian disorders, such as Huntington’s disease and cystic fibrosis (Khoury et 
al, 2000). 
Some authors have therefore called for educational campaigns to improve public 
understanding of genetics (Godard et al, 2003), but others have cautioned that such education 
must build on pre-existing knowledge about disease and genetics (Richards & Ponder, 1996). 
Thus, various organizations and experts argue for a much broader and more wide-ranging 
general public discussion of current and future developments in genetics and their implications 
for public and individual health (Dietrich & Schibeci, 2003; McQueen, 2002; Nuffield Trust, 
2000). The challenge for public education will be to explain the personal and public health 
implications of common polygenic disorders in which individual alleles weakly predict risk and 
interact with each other andwith the person’s environment. If it is done well, such education may 
allay some anxieties that are based on reports of genetic discrimination experienced by some 
patients with mendelian disorders. 
However, public education will have to avoid giving the unintended message that public 
health strategies can be simply replaced by genomic medicine (Merikangas & Risch, 2003; 
Willett, 2002). The best way for many individuals in developed societies to reduce their disease 
risks remains simple: stop smoking, reduce calorie intake and increase exercise (Merikangas & 
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Risch, 2003; Rose, 1992; Vineis et al, 2001). To avoid wholly blaming individuals for their risk 
status, we need to modify our physical and social environments and our social policies, to 
facilitate and sustain desirable changes in risky behaviour. 
There are substantial technical and scientific challenges in realizing the promise of predictive 
genomics in reducing the burden of the common diseases that affect developed societies. One 
major scientific challenge is to identify the more commonly occurring, strongly predictive 
susceptibility alleles for these disorders. Most susceptibility genes that have been identified only 
weakly predict disease risk, so academic and industry researchers need to design tests based on 
multiple alleles to have any prospect of predicting individual risk. Even if such tests can be 
developed, the costs of screening and counselling large populations to identify the small number at 
high risk may be difficult to justify, especially in the absence of effective preventive strategies for 
many conditions. Policy makers also have to consider that population health strategies are more 
efficient in some cases, particularly when it comes to cigarette smoking and preventing heart 
disease. In addition, predictive genomic medicine still needs to tackle many ethical and policy 
issues. Its proponents have to address valid concerns about privacy and the possibility of 
discrimination and abuse of genetic information. Any implementation of genetic testing, whether 
for individuals or larger populations, also has to be accompanied by education campaigns about 
the genetics of common diseases and research on how to present such genetic information in ways 
that motivate behavioural change and do not undermine successful public health strategies. 
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